Conversely, IFN-β was shown to significantly suppress excessive CD40L expression in T cells of MS patients compared to their untreated counterparts, resulting in lower levels of CD3+CD40L+ and CD4+CD40L+ T cells in the treated patients [205] Interestingly, DCs from RRMS patients treated with GA displayed considerably decreased CD40 expression compared to their untreated counterparts, which is associated with relapse risk [206]. Here, CD40 is linked to relapsing-remitting multiple sclerosis.